Clinical Characteristics and Survival Analysis of Breast Cancer Molecular Subtypes with Hepatic Metastases

Ge, Qi-Dong; Lv, Ning; Kong, Ya-Nan; Xie, Xin-Hua; He, Ni; Xie, Xiao-Ming; Wei, Wei-Dong

추천

검색

자료유형: 학술저널

저자정보: Ge, Qi-Dong (Department of Breast Oncology, Sun Yat-sen University Cancer Center) Lv, Ning (Department of Breast Oncology, Sun Yat-sen University Cancer Center) Kong, Ya-Nan (Department of Breast Oncology, Sun Yat-sen University Cancer Center) Xie, Xin-Hua (Department of Breast Oncology, Sun Yat-sen University Cancer Center) He, Ni (State Key Laboratory of Oncology in South China) Xie, Xiao-Ming (Department of Breast Oncology, Sun Yat-sen University Cancer Center) Wei, Wei-Dong (Department of Breast Oncology, Sun Yat-sen University Cancer Center)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제13권 제10호

발행연도: 2012.1

수록면: 5,081 - 5,086 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: The liver is one of the most common metastatic sites of breast cancer, hepatic metastases developing in 6%-25% of patients with breast cancer and being associated with a poor prognosis. The aim of this study was to analyze the survival and clinical characteristics of patients with hepatic metastases from breast cancer of different molecular subtypes and to investigate the prognostic and predictive factors that effect clinical outcome. Methods: We retrospectively studied the charts of 104 patients with breast cancer hepatic metastases diagnosed at Sun Yat-sen University Cancer Center from December 1990 to June 2009. Subtypes were defined as luminal A, luminal B, human epidermal growth factor receptor 2 (HER2) enriched, triple-negative (TN). Prognostic factor correlations with clinical features and treatment approaches were assessed at the diagnosis of hepatic metastases. Results: The median survival time was 16.0 months, and the one-, two- three-, four-, five-year survival rates were 63.5%, 31.7%, 15.6%, 10.8%, and 5.4%, respectively. Median survival periods after hepatic metastases were 19.3 months (luminal A), 13.3 months (luminal B), 18.9 months (HER2-enriched), and 16.1 months (TN, P=0.11). In multivariate analysis, a 2 year-interval from initial diagnosis to hepatic metastasis, treatment with endocrine therapy, and surgery were independent prognostic factors. Endocrine therapy could improve the survival of luminal subtypes (P=0.004) and was a favorable prognostic factor (median survival 23.4 months vs. 13.8 months, respectively, P=0.011). Luminal A group of patients treated with endocrine therapy did significantly better than the Luminal A group of patients treated without endocrine therapy (median survival of 48.9 vs. 13.8 months, P=0.003). Conclusions: Breast cancer subtypes were not associated with survival after hepatic metastases. Endocrine therapy was a significantly favorable treatment for patients with luminal subtype.

#Breast cancer #hepatic metastases #subtypes #prognostic variables #survival analysis

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요